Fanny Legrand1, Jesica Herrick1,2, Michelle Makiya1, Roshan Ramanathan1,3, Reagan Thompson4, Shakuntala Rampertaap5, Jennifer Stoddard5, JeanAnne Ware1, Michael P Fay6, Nicole Holland-Thomas1, Thomas B Nutman1, Amy D Klion1. 1. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA. 2. Division of Infectious Diseases, Immunology and International Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA. 3. Emergent Biosolutions, Gaithersburg, Maryland, USA. 4. University of Virginia Family Medicine, Charlottesville, Virginia, USA. 5. Department of Laboratory Medicine, Warren Magnusson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA. 6. Division of Clinical Research, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.
Abstract
BACKGROUND: Diethylcarbamazine citrate (DEC) treatment of loiasis is complicated by adverse reactions that are correlated with the number of circulating microfilariae (mf). The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. METHODS: To explore the role of IL-5 driven eosinophilia in post-DEC reactions, 8 adults with confirmed loiasis and <5000 mf/mL blood were enrolled in a randomized, double-blind, placebo-controlled trial of the humanized anti-IL-5 antibody, reslizumab, (1.0 mg/kg IV) administered 3 to 7 days prior to initiation of DEC treatment (9 mg/kg/day for 21 days). The primary endpoint was the reduction in absolute eosinophil count (AEC) during the first week of DEC treatment. RESULTS: Baseline characteristics were comparable between the two groups. Single dose reslizumab lowered the AEC by 77% prior to initiation of DEC therapy (vs. 12% in the placebo group, P < .05). More importantly, AEC remained below baseline in the first week of DEC treatment in all subjects who received reslizumab and in none of the placebo subjects. Mf clearance occurred within 2 days of initiation of DEC in all 7 mf-positive subjects. Mild to moderate adverse events were seen in all 8 subjects and were not significantly different between the groups. CONCLUSIONS: In summary, although reslizumab was able to blunt peripheral eosinophilia post-DEC treatment in subjects with loiasis and had no effect on microfilarial clearance, the reduction in AEC appeared to have been insufficient to prevent post-treatment AEs. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Diethylcarbamazine citrate (DEC) treatment of loiasis is complicated by adverse reactions that are correlated with the number of circulating microfilariae (mf). The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. METHODS: To explore the role of IL-5 driven eosinophilia in post-DEC reactions, 8 adults with confirmed loiasis and <5000 mf/mL blood were enrolled in a randomized, double-blind, placebo-controlled trial of the humanized anti-IL-5 antibody, reslizumab, (1.0 mg/kg IV) administered 3 to 7 days prior to initiation of DEC treatment (9 mg/kg/day for 21 days). The primary endpoint was the reduction in absolute eosinophil count (AEC) during the first week of DEC treatment. RESULTS: Baseline characteristics were comparable between the two groups. Single dose reslizumab lowered the AEC by 77% prior to initiation of DEC therapy (vs. 12% in the placebo group, P < .05). More importantly, AEC remained below baseline in the first week of DEC treatment in all subjects who received reslizumab and in none of the placebo subjects. Mf clearance occurred within 2 days of initiation of DEC in all 7 mf-positive subjects. Mild to moderate adverse events were seen in all 8 subjects and were not significantly different between the groups. CONCLUSIONS: In summary, although reslizumab was able to blunt peripheral eosinophilia post-DEC treatment in subjects with loiasis and had no effect on microfilarial clearance, the reduction in AEC appeared to have been insufficient to prevent post-treatment AEs. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
zzm321990 Loa loazzm321990 ; diethylcarbamazine; eosinophil; filariasis; interleukin-5
Authors: Todd M Wilson; Irina Maric; Juhi Shukla; Margaret Brown; Carlo Santos; Olga Simakova; Paneez Khoury; Michael P Fay; Alexander Kozhich; Roland Kolbeck; Dean D Metcalfe; Amy D Klion Journal: J Allergy Clin Immunol Date: 2011-07-16 Impact factor: 10.793
Authors: Jesica A Herrick; Simon Metenou; Michelle A Makiya; Cheryl A Taylar-Williams; Melissa A Law; Amy D Klion; Thomas B Nutman Journal: Clin Infect Dis Date: 2014-09-18 Impact factor: 9.079
Authors: Amy D Klion; Melissa A Law; Pierre Noel; Yae-Jean Kim; Thomas P Haverty; Thomas B Nutman Journal: Blood Date: 2003-12-24 Impact factor: 22.113
Authors: Samuel Wanji; Ebanga-Echi Eyong; Nicholas Tendongfor; Che Ngwa; Elive Esuka; Arnaud Kengne-Ouafo; Fabrice Datchoua-Poutcheu; Peter Enyong; Adrian Hopkins; Charles D Mackenzie Journal: PLoS Negl Trop Dis Date: 2015-11-10